Planning SMARTs: Sample size estimation for comparing dynamic treatment regimens using longitudinal count outcomes with excess zeros

JAMIE YAPª, JOHN DZIAK^b, RAJU MAITI^c, KEVIN LYNCH^f, JAMES R. MCKAY^{f,g}, BIBHAS CHAKRABORTY^{c,d,e}, INBAL NAHUM-SHANI^a

a Institute for Social Research, Ann Arbor, MI, USA

bBennett Pierce Prevention Research Center, Pennsylvania State University, PA, USA

^cCentre for Quantitative Medicine, Duke-NUS Medical School, Singapore

^dDepartment of Statistics and Applied Probability, National University of Singapore, Singapore

^eDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA

^fDepartment of Psychiatry, University of Pennsylvania, PA, USA

^gPhiladephia Veterans Affairs Medical Center, PA, USA

jamieyap@umich.edu

Summary

In many health domains such as substance-use, outcomes are often counts with an excessive number of zeros (EZ) – count data having zero counts at a rate significantly higher than that expected of a standard count distribution (e.g., Poisson). However, an important gap exists in sample size estimation methodology for planning sequential multiple assignment randomized trials (SMARTs) for comparing dynamic treatment regimens (DTRs) using longitudinal count data. DTRs, also known as *treatment algorithms* or *adaptive interventions*, mimic the individualized and evolving nature of patient care through the specification of decision rules guiding the type, timing and modality of delivery, and dosage of treatments to address the unique and changing needs of individuals. To close this gap, we develop a Monte

Carlo-based approach to sample size estimation. A SMART for engaging alcohol and cocainedependent patients in treatment is used as motivation.

Key words: correlated count data; dynamic treatment regimen; longitudinal data analysis; sample size estimation; sequential multiple assignment randomized trial; zero-inflation

1. Introduction

A dynamic treatment regimen (DTR) is characterized by a sequence of treatments provided at different stages and individualized based on *tailoring variables* – baseline and ongoing information from the individual used to guide whether and how to modify treatment for the individual (Collins, Murphy, and Bierman, 2004). As a means to operationalize the sequential and individualized decision making in the provision of patient care, particularly in the treatment of chronic behavioral or physical health conditions, DTRs enable effective resource allocation and hold promise in decreasing the economic burden of poor health.

The sequential multiple assignment randomized trial (SMART) is a useful experimental approach for obtaining the empirical evidence necessary for the construction of an effective DTR. A SMART (Lavori and Dawson, 2000; Murphy, 2005) involves multiple stages of randomization with each stage beginning with a decision point in which some or all individuals are randomized among the appropriate intervention options. As an example, consider the SMART in Figure 1 to develop a DTR for engaging alcohol and cocaine-dependent patients in treatment. Intensive Outpatient Programs (IOPs) are the most common kind of treatment programs offered to individuals with relatively severe substance-use disorders. However, many individuals do not attend the IOP therapy sessions and hence are less likely to benefit from the program (McKay et al., 2015). The purpose of this study was to determine whether at the first intervention stage, it is better to offer motivational interviewing (MI)-based outreach efforts that focus on helping the individual to engage in the IOP (MI-Engage) or MI-based outreach efforts that includes offering the individual additional customization options (MI-Choice), and to determine the best second-stage course of action for participants who do not respond to the initial outreach efforts. Alcohol and cocaine-dependent individuals were recruited when they entered IOP treatment, and their treatment attendance was tracked for 8 weeks. Those who failed to engage in the IOP by the 2nd week entered into the SMART and were randomized to MI-Engage or MI-Choice. At month 2 (i.e., two months after entering IOP treatment), participants showing signs of non-response were re-randomized to either MI-Choice or no further contact; all participants showing signs of response received no further contact (i.e., responders were not rerandomized). This experimental design has four DTRs *embedded* (EDTRs) within the design, and resulted in 6 cells, labeled A-F in Figure 1.

A longitudinal outcome assessing the number of past-month cocaine-use days was collected at the end of months 1 to 6. For ease of exposition, throughout, we will assume that randomization to the first-stage intervention options in the ENGAGE SMART instead occurred immediately after the end of month 1 (i.e., one month after entering IOP treatment), coinciding with the first measurement occasion. Among individuals who follow the six paths leading to cells A-F in Figure 1, means, variances, and rates of zeros (i.e., proportion of individuals having no cocaine-use days in the past month) across measurement occasions range from 0.51 to 7.71, 3.77 to 112.07, and 0.36 to 0.89, respectively. These summary statistics exemplify count data with excess zeros (EZ) which are characteristic of outcomes in a wide variety of health domains (e.g., counts of past-month heavy drinking days (Lei et al., 2012).

A variety of sample size planning resources have been developed for SMARTs having continuous-, binary-, or survival- type end-of-study or longitudinal outcomes (e.g., Li and

Murphy, 2011; Kidwell et al., 2018; Seewald, et al., 2020). However, a gap in the literature remains concerning sample size planning resources for the comparison of EDTRs in SMARTs using longitudinal count outcomes, particularly those having EZ. To our knowledge, this is the first manuscript proposing an approach to fill this gap.

We begin by describing the inferential target for longitudinal count outcomes with EZ (Section 2) and considerations in developing a Monte Carlo-based approach to sample size estimation for comparing EDTRs using longitudinal count data with EZ (Section 3). The proposed approach to sample size estimation is introduced (Section 4), simulation studies investigating its validity are described (Section 5 and 6). Finally, directions for future research are discussed (Section 7).

2. Hypothesis tests for comparing DTRs embedded in a SMART

In this manuscript, we will focus on one of the most common SMART designs exemplified by the ENGAGE study: a *two-stage restricted SMART.* In this design, there are two first-stage intervention options, and two second-stage intervention options where the decision on whether to randomize individuals to second-stage intervention options is determined based on a tailoring variable. In the most common type of SMART, the tailoring variable is the individual's *response status* – an indicator for whether sufficient progress was achieved during the first stage of treatment – and only individuals classified as *non-responders* are re-randomized to secondstage intervention options.

2.1 Focusing on overall means of EZ vs. means for two distinct sub-populations

Count data with EZ are often postulated to be drawn from a mixture of two distinct subpopulations of individuals: one set of individuals for whom it would not be possible to observe non-zero counts (i.e., the *non-susceptible subpopulation*), and another set of individuals for whom it would be possible to observe either zero or non-zero counts (i.e., the *susceptible subpopulation*). Hence, count data with EZ is sometimes described using a mixture model that contains two parts: one model for the probability of belonging to the non-susceptible subpopulation and another model for the mean of outcomes in the susceptible subpopulation. However, it has been noted by various authors (e.g., (Albert, Wang, and Nelson, 2014) that primary scientific questions in clinical trials typically do not concern the source of the excess zeros, but rather, the overall mean across the two sources, i.e., the treatment effect in the *entire population*. Hence, this manuscript focuses on developing an approach to sample size estimation for the case when EDTRs are compared based on *overall means* of a longitudinal count outcome.

2.2 Notation for quantities associated with EDTRs

Denote an EDTR in Figure 1 by (a_1, a_2^{NR}) where a_1 is a first-stage intervention option and a_2^{NR} is a second-stage intervention option offered to non-responders; $a_1 = \{+1, -1\}$ and $a_2^{NR} = \{+1, -1\}$. Let t_j denote the time of the j^{th} measurement occasion where $j =$ $1, ..., K, ..., T$. Here, we use K to represent the specific time point immediately before the second randomization occurs and T to represent the total number of measurement occasions. We assume that all individuals have measurements at each t_j . Let Y_{i,t_j} denote a count outcome of an individual *i* that was observed during the actual conduct of the trial at time t_j (e.g., number of cocaine-use days over month t_j). Let $Y_{i,t_j}^{(a_1,a_2^{NR})}$ denote a count outcome of an individual *i* that would have been observed at time t_j had the individual followed EDTR (a_1, a_2^{NR}) . The outcome $Y_{i,t_j}^{(a_1,a_2^{NR})}$ is also known as the *potential outcome* (Rubin, 2005) of individual *i* at time t_j under EDTR (a_1, a_2^{NR}) . Finally, we define the *mean trajectory* of *EDTR* (a_1, a_2^{NR}) as $\mathcal{T}^{(a_1, a_2^{NR})}$:= $\{\mu_{t_j}^{(a_1, a_2^{NR})}: j = 1, ..., K, ..., T\}$ where $\mu_{t_j}^{(a_1, a_2^{NR})}$ denotes $E\{Y_{i,t_j}^{(a_1, a_2^{NR})}\}$.

2.3 Primary aims of a SMART

The comparison of a pair of EDTRs based on difference in end-of-study means is the most common primary aim in SMARTs. While not as popular, the comparison of a pair of EDTRs based on difference in *Area Under the Curve (AUC)* (Lu et al., 2016) is an appealing alternative primary aim that accounts for how mean trajectories of EDTRs evolve over time. AUC is defined as the total area under $\mathcal{T}^{(a_1, a_2^{NR})}$ between time t_{j_1} and time t_{j_2} . Approximating AUC between t_1 and t_T using the trapezoidal rule, $AUC^{(a_1, a_2^{\text{NR}})} \coloneqq \sum_{j=1}^{T-1} \frac{1}{2}$ $T-1 \frac{1}{2} \left[\mu_{t_j}^{(a_1, a_2^{NR})} + \right]$

 $\mu_{t_{j+1}}^{(a_1,a_2^{NR})}$ $(t_{j+1}-t_j)$. In contrast to end-of-study outcomes, AUC captures the process of change in the longitudinal outcome over time. For example, when the longitudinal outcome is the number cocaine-use days in the past month prior to time t_j , *average AUC* between time t_1 and time t_T , defined as $\frac{\text{AUC}}{t_T-t_1}$, is the average number of past-month cocaine-use days over a period of length $t_T - t_1$. More generally, any particular pair of EDTRs $(a_1', a_2^{NR'})$ and $(a_1'', a_2^{NR''})$ can be compared based on the difference $\Delta_Q := \sum_{j=1}^T l_j \mu_{t_j}^{(a_1',a_2^{NR'})} - \sum_{j=1}^T l_j \mu_{t_j}^{(a_1'',a_2^{NR''})}$ where l_j 's are real valued constants. Δ_0 can be viewed as the difference of weighted sums with weights given by the l_j 's, which need not sum to 1. The choice of l_j 's can make Δ_Q equivalent to end-ofstudy means (e.g., by setting the T^{th} weight to be equal to 1 and all other weights equal to zero), AUC (e.g., by setting the 1st weight to be equal to $\left(\frac{t_2-t_1}{2}\right)$ $\left(\frac{-t_1}{2}\right)$, the T^{th} weight to be equal to $\frac{t_T-t_{T-1}}{2}$ $\frac{t_{T-1}}{2}$), and all other weights to be equal to $\left(\frac{t_{j+1}-t_{j-1}}{2}\right)$ $\frac{q-1}{2}$), or other estimands. Here, we propose an approach to estimate sample size required to attain power of $1 - \eta$ to reject the null hypothesis $H_0: \Delta_0 = 0$ against the alternative $H_a: \Delta_0 \neq 0$ at type-I error α .

2.4 Modeling and estimation of EDTR mean trajectories

Let $I(\cdot)$ denote an indicator function. We utilize a piece-wise model for $\mu_{t_j}^{(a_1, a_2^{NR})}$ expressed in terms of stage-specific quantities and displayed in Equation 1 where mean trajectories of all EDTRs in a SMART are constrained to share the same intercept while the mean trajectories of a pair of EDTRs that only differ in a_2^{NR} are constrained to be identical until time t_K , but allowed to differ after time t_K . The parameters in Equation 1 can be estimated using the inverse probability weighted and replicated estimator (IPWRE) proposed by Lu and colleagues (Lu et al., 2016). In other words, for each EDTR, each measurement occasion j is given its own parameter in Equation 1.

$$
\log(\mu_{t_j}^{(a_1, a_2^{NR})}) = \beta_{1,1} + I(a_1 = +1) \cdot I(1 < j \le K) \cdot \beta_{2,j} \tag{1}
$$
\n
$$
+ I(a_1 = -1) \cdot I(1 < j \le K) \cdot \beta_{3,j}
$$
\n
$$
+ I(a_1 = +1, a_2^{NR} = +1) \cdot I(K < j \le T) \cdot \beta_{4,j}
$$
\n
$$
+ I(a_1 = +1, a_2^{NR} = -1) \cdot I(K < j \le T) \cdot \beta_{5,j}
$$
\n
$$
+ I(a_1 = -1, a_2^{NR} = +1) \cdot I(K < j \le T) \cdot \beta_{6,j}
$$
\n
$$
+ I(a_1 = -1, a_2^{NR} = -1) \cdot I(K < j \le T) \cdot \beta_{7,j}
$$
\n
$$
(1)
$$

2.5 Hypothesis testing and power of the test

Let β denote a vector whose components are the $4T - 2K - 1$ parameters of Equation 1 and $\hat{\beta}^{IPWRE}$ and $\hat{\Delta}_{Q}^{IPWRE}$ denote an estimate of β and Δ_{Q} , respectively, obtained using IPWRE. Lu and colleagues (see Theorem I.2 in Supplementary Material of Lu and colleagues (Lu et al., 2016)) showed that $\hat{\mathbf{\beta}}^{IPWRE}$ is consistent and asymptotically multivariate normal (MVN) distributed. Based on this work, and using the delta method (Taylor linearization), we show that

the quantity $\widehat{Var}(\widehat{\Delta}_{Q}^{IPWRE})$ can be expressed in terms of $\widehat{Var}(\widehat{\pmb{\beta}}^{IPWRE})$ and that Theorem 2.1 holds (see Web Appendix A and Web Appendix B for details).

Theorem 2.1:
$$
Z := \frac{\widehat{\Delta}_{Q}^{IPWRE} - \Delta_{Q}}{\sqrt{Var(\widehat{\Delta}_{Q}^{IPWRE})}}
$$
 is $Normal(0,1)$ distributed.

Let z_q denote the q^{th} percentile of the standard normal distribution, α denote type-I error rate, η

denote type II error rate. A Z-test is to reject H_0 if $\frac{\hat{\Delta}_Q^{IPWRE}}{\sqrt{2\pi\hat{Q}^{IPWRE}}}$ $\sqrt{Var\left(\hat{\Delta}_{Q}^{IPWRE}\right)}$ $\vert > z_{1-\alpha/2}$. The power of the

test is thus
$$
1 - \eta \approx Pr_{H_a} \left\{ \left| \frac{\partial_0^{IPWRE}}{\sqrt{\widehat{var}(\widehat{\Delta}_0^{IPWRE})}} \right| > z_{1-\alpha/2} \right\}.
$$

3. Considerations in developing a Monte Carlo-based approach to sample size estimation Deriving a closed-form sample size formula necessarily involves expressing the variance term in the denominator of the Z-statistic in terms of quantities which are interpretable by

clinical/behavioral experts. This variance term, which was derived by Lu and colleagues (see Theorem I.2 in Supplementary Material of Lu and colleagues (Lu et al., 2016)), is not analytically tractable as functions of the model parameters of interest, particularly when the total number of measurement occasions, T, is large. Hence, this manuscript adopts a Monte Carlobased approach to enable clinical/behavioral experts to estimate sample size for arbitrary T .

3.1 Considerations relating to the planned SMART design

It is important for the data generation step in a Monte Carlo-based approach to accommodate salient features of realistic SMART designs, including the multiple sequential randomizations, re-randomization of non-responders based on a tailoring variable, ordering of the sequential randomizations in a SMART in relation to the timing of repeated measurements, and dependency between the tailoring variable and the repeated measurements. These features,

which are not typical of RCTs with longitudinal data, introduce substantial complexity to the data generation step, particularly when simulating counts with EZ. Another consideration is ensuring interpretability of *design parameters* – parameters that serve as inputs to sample size estimation – based on existing evidence (e.g., pilot studies, published scientific literature, practical considerations). In the authors' collective experience planning SMARTs, clinical/behavioral experts typically have found the overall means at the EDTR-level abstract and difficult to specify, but specification of the overall means at the level of *Embedded Treatment Sequences (ETS)* more tractable. In contrast to an EDTR, an ETS refers to a sequence of intervention options offered in practice to an individual by time t_j . That is, starting at time t_K , an ETS is conditional on the tailoring variable while an EDTR is marginal over the tailoring variable.

In the SMART literature, approaches for generating longitudinal outcomes from twostage restricted SMARTs are limited in various aspects. For example, in some simulation studies (e.g., (Miyahara and Wahed, 2012; Lu et al., 2016), data is generated such that the repeated measurements prior to the second-stage randomization are treated as independent of the tailoring variable. However, this is not a realistic assumption in practice (e.g., see (Lei et al., 2012)). In other cases (e.g., Appendix 3 in (Seewald, et al., 2020)), the tailoring variable is closely related to the repeated measurements, but EDTR-level quantities are required as inputs to generate data.

3.2 Considerations relating to the distribution of count data

Our approach to sample size estimation will be described using a negative binomial (NB) distribution, given by Equation 2 where a univariate random variable Y denotes the number of events during specified time period, e.g., counts of cocaine-use days within the past one-month, and $\Gamma(\cdot)$ is the gamma function. When the distribution of Y is given by Equation 2, i.e.,

 $Y \sim NB(\mu, \zeta)$, the dispersion parameter is ζ , while the mean and variance of Y are μ and $\mu + \zeta \mu^2$, respectively. Further, the probability of zero counts in Y is $\left(\frac{\zeta^{-1}}{n+1}\right)$ $\frac{5}{\mu+\zeta^{-1}}$ ζ^{-1} .

$$
f_{NB(\mu,\zeta)}(y) = \frac{\Gamma(\zeta^{-1} + y)!}{\Gamma(\zeta^{-1})! \, y!} \pi^{\left(\zeta^{-1}\right)} (1 - \pi)^y \text{ where } \pi = \frac{\zeta^{-1}}{\mu + \zeta^{-1}} \tag{2}
$$

Although the NB distribution has been conventionally used to characterize overdispersion in count data, we argue that the NB distribution can also serve as a parsimonious characterization of EZ. Too see why this can be the case, observe that higher values in the dispersion parameter ζ impose increased variance (i.e., $\mu + \zeta \mu^2$ approaches infinity) and increased proportion of zeros (i.e., $\left(\frac{\zeta^{-1}}{1+\zeta^{-1}}\right)$ $\frac{5}{\mu+\zeta^{-1}}$ ζ^{-1} approaches 1) relative to a Poisson distribution with the same mean.

4. Methods

We use ideas from two areas in the statistical literature, namely, the potential outcome framework and copulas to devise an approach to simulate count data with EZ from a two-stage restricted SMART. Copulas are functions that link together marginal univariate cumulative distribution functions to form a multivariate cumulative distribution function (CDF) (e.g., see (Song, 2000)). Copulas can be utilized in a data-generative model to simulate multivariate nonnormal random variables whose marginal univariate distributions could be specified independently of the targeted correlation structure prior to data generation. Although a variety of copulas exist in the literature, the Gaussian copula was selected due to practical considerations relating to computational efficiency. Equation 3 defines a Gaussian copula; X_1, \ldots, X_d represent random variables comprising the components of the multivariate random variable of interest, F_{X_i} 's are marginal univariate CDFs of the X_i 's, Φ_d denotes the standard d-dimensional

multivariate normal CDF, ϕ denotes the univariate standard normal CDF, and Λ_d denotes a $d \times d$ positive definite symmetric matrix that governs the dependence among the X_i 's.

$$
F_{X_1...X_d}(x_1...x_d) = \Phi_d\left(\phi^{-1}\left(F_{X_1}(x_1)\right) \dots \phi^{-1}\left(F_{X_d}(x_d)\right); \Lambda_d\right) \tag{3}
$$

The notion of copulas in a data-generative model to simulate non-normal potential outcomes is not new. Outside the SMART setting, several authors (e.g., (Albert and Nelson, 2011)) have used a Gaussian copula (Song, 2000) to specify the joint distribution of non-normal potential outcomes. Using copulas in data generation will require generating each component of a multivariate random variable at the same time. Although it is impossible to determine the sequence of interventions that would actually be offered to an individual prior to first-stage randomization, it is possible to enumerate an individual's full set of potential outcomes with respect to each ETS prior to data generation, a fact that is exploited in our proposed approach.

4.1 Notation for quantities associated with ETS

We let Y_{i,t_j}^s denote a count outcome of individual *i* that would have been observed at time t_j had the individual undergone a particular ETS s and let $\mu_{t_j}^s$ denote $E\left\{Y_{i,t_j}^s\right\}$. We note that there are four EDTRs in the SMART design we consider, regardless of time. However, the number of ETSs associated with time t_j is determined by when t_j occurred in relation to first-stage randomization and second-stage randomization. Prior to first-stage randomization (i.e., at time $t₁$) an individual would not be offered any of the intervention options, hence, we denote this as $(·)$ and observe that Figure 1 displays only one ETS by the end of time t_1 . After first-stage randomization but prior to second-stage randomization (i.e., when $t_2 \le t_j \le t_K$) only the firststage intervention would have been offered; hence, we denote this as (a_1) and observe that Figure 1 displays two possible ETSs at time t_j . After the assessment of response status (i.e.,

when $t_{K+1} \le t_j \le t_T$), second-stage intervention options would have been offered to nonresponders, whereas responders would not get re-randomized. Hence, we denote the ETS as (a_1, r, a_2^{NR}) and observe that Figure 1 displays six ETSs at time t_j . By convention, we set $a_2^{NR} =$ 0 if response $(r=1)$ to a_1 was observed; $a_2^{NR} = \pm 1$ if non-response $(r=0)$ was observed.

4.2 Criterion for non-response

For simplicity, we assume that in the SMART being planned, a given individual will be classified as a responder if the outcome immediately prior to the second randomization at time t_K does not exceed a pre-specified cut-point c , and a non-responder otherwise. In other words, let $R_i^{(a_1)}$ denote response status for an individual *i* that would have been observed had the individual undergone first-stage intervention a_1 , then $R_i^{(a_1)} = I\left(Y_{i,t_K}^{(a_1)} \le c\right)$. Similarly, for observed outcomes, let $R_i = I(Y_{i,t_K} \leq c)$. In the health domain of substance-use, choosing the cut-point to be zero can be interpreted as classifying individuals who failed to abstain from past-month substance-use at time t_K as *non-responders*. Once a criterion for non-response has been defined, the magnitude of Δ_0 can be re-expressed in terms of quantities associated with ETSs as in Equation 4 where p and q denote the probabilities $Pr\left\{R_i^{(a_1')} = 1\right\}$ and $Pr\left\{R_i^{(a_1'')} = 1\right\}$, respectively. Equation 4 displays the equation by which eliciting p, q, and $\mu_{t_j}^s$'s (either directly or indirectly) from clinical/behavioral experts allows the determination of the desired magnitude Δ ₀ in the planned SMART.

$$
\Delta_{Q} := \sum_{j=2}^{K} l_{j} \left\{ \mu_{t_{j}}^{(a_{1})} \right\} - \sum_{j=2}^{K} l_{j} \left\{ \mu_{t_{j}}^{(a_{1})} \right\} + \sum_{j=K+1}^{T} l_{j} \cdot \left\{ p \mu_{t_{j}}^{(a_{1}',1,0)} + (1-p) \mu_{t_{j}}^{(a_{1}',0,a_{2}^{NR'})} \right\}
$$

$$
- \sum_{j=K+1}^{T} l_{j} \cdot \left\{ q \mu_{t_{j}}^{(a_{1}'',1,0)} + (1-q) \mu_{t_{j}}^{(a_{1}'',0,a_{2}^{NR''})} \right\}
$$

$$
(4)
$$

4.3 Data generation

To simplify exposition, within Section 4.3, we suppose that only three measurement occasions are to be collected (i.e., $T=3$) in a planned two-stage restricted SMART with design depicted in Figure 1: prior to first-stage randomization (t_1) , prior to second-stage randomization $(t_K; K = 2)$, and post-second stage randomization at end-of-study $(t_T; T = 3)$. However, the approach is applicable to more measurement occasions; *design parameters* required are:

- 1. Total number of individuals N; the criterion Δ_{Q} ; desired type-I error rate α .
- 2. c , the cut-point used to determine response status to first-stage intervention options.
- 3. The means of the longitudinal EZ count outcome for all ETSs s and time points t_j , i.e., the quantities μ_{i,t_j}^s for all ETSs *s* and time points t_j .
- 4. The proportion of zeros in the longitudinal EZ count outcome for all ETSs s and time points t_j , i.e., the quantities $Pr\left\{Y_{i,t_j}^s = 0\right\}$ for all ETSs s and time points t_j .
- 5. τ_{MAX} , the *maximum* within-person correlation among longitudinal outcomes Y_{i,t_j}^s across all pairs of ETSs s' and s'' and pairs of time points $t_{j'}$ and $t_{j''}$. That is, τ_{MAX} :

$$
\max_{s',s'',\ t_{j'},t_{j''}} \Big\{Corr\left(Y_{i,t_{j'}}^{s'},Y_{i,t_{j''}}^{s''}\right)\Big\}.
$$

Enumerating an individual's complete set of potential outcomes

The proposed approach to generating data assumes that each individual entering a SMART belongs to one of several mutually exclusive subgroups. Specifically, under the

potential outcome framework, each individual entering a two-stage restricted SMART depicted in Figure 1 can be thought of as belonging to one of four mutually exclusive subgroups based on whether they would respond to each first-stage intervention option: *subgroup 1* refers to those who would respond to both $a_1 = +1$ and $a_1 = -1$; *subgroup* 2 refers to those who would respond to $a_1 = +1$ but not to $a_1 = -1$; *subgroup 3* refers to those who would not respond $a_1 =$ +1 but would respond to $a_1 = -1$; *subgroup 4* refers to those who would not respond to either $a_1 = +1$ and $a_1 = -1$. This is similar to the notion of "always survivor", "never survivor", "protectable", and "defier" subgroups introduced by Frangakis and colleagues (Frangakis, et al., 2007), although with different group definitions suited to the SMART context. Now, observe that it is impossible for individuals who are members of subgroup 1 to undergo the sequence (a_1 = +1, $r = 0$, $a_2^{NR} = +1$) by the end of the third measurement occasion t_3 and hence, the potential outcome $Y_{i,t_3}^{(a_1=+1,r=0,a_2^{NR}=+1)}$ is undefined for these individuals. An analogous observation could be made involving other subgroups and measurement occasions (see Web Table 2). Hence, an individual's complete set of potential outcomes can be enumerated by specifying all the potential outcomes Y_{i,t_j}^s 's that would be feasible for the individual, contingent on their subgroup membership.

Specification of the joint distribution of an individual's complete set of potential outcomes

Let θ_i^j denote a vector of potential outcomes of individual *i* belonging to subgroup *j*. A Gaussian copula is used to specify a multivariate cumulative distribution function (CDF) for $\mathbf{\theta}_i^j$ such that the marginal distributions, i.e., the univariate distribution of a specific component of θ_i^j marginal over all the other components of θ_i^j , adhere to a desired univariate CDF (e.g., a NB CDF). Since the dimension of θ_i^j differs across subgroups, a different Gaussian Copula should be

specified for each subgroup. Specifically, θ_i^j is a 5-dimensional for subgroup 1 (j=1), 6dimensional for subgroups 2 and 3 ($j=2$ and 3), 7-dimensional for subgroup 4 ($j=4$). For each subgroup, the univariate CDFs $F_{X_{\ell}}$'s in Equation 3 are chosen to be the CDFs of count distributions. While there is flexibility in the choice of these univariate CDFs, the fact that response status is defined in terms of a cut-point constrains the maximum or minimum possible value of the potential outcome under either first-stage intervention at time of the K^{th} measurement occasion (i.e., at t_2 in this case). For example, for individuals who belong to Subgroup 2 (i.e., those individuals who would respond to $a_1 = +1$ but not to $a_1 = -1$), the value of $Y_{i,t_K}^{(+1)}$ is at most c while the value of $Y_{i,t_K}^{(-1)}$ is greater than c, i.e., $Y_{i,t_K}^{(+1)} \le c$ and $Y_{i,t_K}^{(-1)}$ c. The constraints on $Y_{i,t_{\rm K}}^{(+1)}$ and $Y_{i,t_{\rm K}}^{(-1)}$ for the remaining subgroups can be analogously specified (see Web Table 3). The constraints on $Y_{i,t_K}^{(+1)}$ and $Y_{i,t_K}^{(-1)}$ for each subgroup thus inform our choice of univariate CDFs F_{X_ℓ} 's to utilize in the specification of a subgroup-specific Gaussian copula. Specifically, for potential outcomes corresponding to ETS s at the K^{th} measurement occasion (i.e., at t_2 in this case), we choose a truncated NB CDF defined by $F(w^*)$: = $Pr{W \le w^*}$ = $\sum_{i=0}^{w^*} f(w)$. Equation 5 and Equation 6 define the function $f(w)$ if the constraints on Y_{i,t_K}^s involve ' \leq ' or ' $>$ ', respectively. We note that when c=0, $f(w)$ reduces to a point mass at zero if the constraint on Y_{i,t_K}^s in involves ' \leq '.

$$
f(w) = \frac{f_{NB\left(\mu_{t_K}^s, \zeta_{t_K}^s\right)}(w)I(w \le c)}{\sum_{y=0}^c f_{NB}\left(\mu_{t_K}^s, \zeta_{t_K}^s\right)(y)}
$$
(5)

$$
f(w) = \frac{f_{NB\left(\mu_{t_K}^s, \zeta_{t_K}^s\right)}(w)I(w > c)}{1 - \sum_{y=0}^c f_{NB\left(\mu_{t_K}^s, \zeta_{t_K}^s\right)}(y)}
$$
(6)

On the other hand, for potential outcomes corresponding to ETS s at any of the other measurement occasions, we choose a NB CDF defined by $F(w^*)$: = $Pr{W \leq w^*}$ = $\sum_{W=0}^{W^*} f$ ${}_{w=0}^{w^*} f_{NB\left(\mu_{t_j}^s,\zeta_{t_j}^s\right)}(w); j \neq K$. The complete specification of the univariate CDFs of the Gaussian copula for each subgroup is displayed in Web Table 4 and Web Table 5.

Now, we turn our attention to Λ_d to complete the specification of a joint distribution for θ_i^j . Note that the correlation between the X_i 's in Equation 3 is determined not only by the choice of Λ_d , but also by the marginal univariate CDFs (i.e., the F_{X_i} 's); in general, the correlation between the X_i 's is unavailable in closed-form but can be estimated using Monte Carlo methods (e.g., see (Song, 2000)). Hence, to enable tractability of this numerical estimation, we will use an exchangeable matrix for Λ_d with ρ on its off-diagonals; the same parameter ρ , which we will refer to as the *dependence parameter* in the copula, will be utilized across all four subgroups. A grid search (see Web Appendix D for details) will be employed to determine the value of ρ to utilize in the Gaussian copula (i.e., Equation 3) for each subgroup; the grid search considers a range of values for ρ within −1 to 1 such that Λ_d will be positive definite, e.g., when −0.16 ≤ $\rho \leq 1$, Λ_5 , Λ_6 , and Λ_7 will be positive definite.

Generating an individual's complete set of potential outcomes

Once the specification of a Gaussian copula for each subgroup is complete, a method proposed by Madsen and Birkes (Madsen and Birkes, 2013), which involves initially drawing from a MVN distribution and applying a series of non-linear transformations, can then be directly applied to simulate multivariate non-normal data according to a pre-specified distribution of the multivariate (potential) outcome θ_i^j (see Web Appendix C for details).

Simulating sequential randomizations to generate an individual's observed outcomes

Once the complete set of potential outcomes for each of the N individuals have been generated, observed outcomes are chosen based on simulated sequential randomizations and the potential outcome framework's consistency assumption (Rubin, 2005). This assumption states that an individual's observed outcome is equal to their potential outcome under the intervention that was offered during the actual conduct of the trial. This implies that for the particular set of values (a_1) and (a_1, r, a_2^{NR}) pertaining to individual *i*, we have that $Y_{i,t_1} = Y_{i,t_1}^{(\cdot)}$, that Y_{i,t_2} = $Y_{i,t_2}^{(a_1)}$, that $R_i = R_i^{(a_1)}$, that $Y_{i,t_3} = Y_{i,t_3}^{(a_1,1,0)}$ if $R_i = 1$, and $Y_{i,t_3} = Y_{i,t_3}^{(a_1,0,a_2^{NR})}$ if $R_i = 0$.

Specifying the number of individuals to generate per subgroup

We describe how the number of individuals generated per subgroup is determined based on the design parameters specified above (at the onset of Section 4.3). First, the specified values for $Pr\left\{Y_{i,t_K}^{(+1)}=0\right\}$, $\mu_{i,t_K}^{(+1)}$, $Pr\left\{Y_{i,t_K}^{(-1)}=0\right\}$, and $\mu_{i,t_K}^{(-1)}$ and the NB density displayed in Equation 2 can be used to solve for the corresponding value of the dispersion parameters $\zeta_{i,t_K}^{(+1)}$ and $\zeta_{i,t_K}^{(-1)}$. Subsequently, the probability of response to either first-stage intervention given a particular cutpoint c, i.e., $Pr\left\{Y_{i,t_K}^{(a_1)} \leq c\right\}$ can now be calculated using the NB density displayed in Equation 2. Next, let n_i denote the number of individuals that would belong to subgroup *j* and $\lceil \cdot \rceil$ denote the ceiling function, respectively. Under the working assumption that the number of individuals in subgroup 4 is equal to the minimum of the number of non-responders to either first-stage intervention, i.e., $n_4 = \min\{N(1 - p), N(1 - q)\}\$, the number of individuals to generate for each subgroup can then be obtained by solving for the n_j 's in Equation 7 and then calculated as $|n_j|$. We note that our working assumption is equivalent to setting n_4 to its maximum possible value; the actual range of possible values for n_4 is between 0 to min{N(1 – p), N(1 – q)}.

$$
\begin{cases}\nN = n_1 + n_2 + n_3 + n_4 \\
p = \frac{n_1 + n_2}{N} \\
q = \frac{n_1 + n_3}{N} \\
n_4 = \min\{N(1 - p), N(1 - q)\}\n\end{cases} (7)
$$

4.4 Power calculation for a fixed sample size N

Let \mathbb{P}_M denote an empirical mean across M simulated datasets. We estimate power using

$$
\mathbb{P}_M\left\{I\left(\left|\frac{\hat{\Delta}_Q^{IPWRE}}{\sqrt{\text{Var}\left(\hat{\Delta}_Q^{IPWRE}\right)}}\right| > z_{1-\alpha/2}\right)\right\}, \text{ calculated as follows:}
$$

- 1. Values for design parameters under the alternative hypothesis (H_a) are specified.
- 2. Select an appropriate value of the copula dependence parameter ρ (see Web Appendix D for more detail).
- 3. A large number of simulated SMART datasets, M , consisting of N individuals each would be generated based on these values; the method of data-generation would follow that described in Section 4.3. For each of the M simulated datasets, data from all N individuals will be used to calculate \hat{A}^{IPWRE}_{Q} and $\hat{Var}(\hat{\Delta}^{IPWRE}_{Q})$.
- 4. Finally, power is calculated as the proportion of simulated datasets for which the

inequality
$$
\left| \frac{\hat{\Delta}_{Q}^{IPWRE}}{\sqrt{\hat{var}(\hat{\Delta}_{Q}^{IPWRE})}} \right| > z_{1-\alpha/2}
$$
 holds.

When power calculation is repeated for a grid of sample sizes, e.g., 100, 150, ..., 600, to produce a power curve, the sample size needed to attain power, say 0.80, can be determined by selecting the value of N where power first exceeds 0.80.

5. Simulation Study Design

Throughout this section, we consider a prototypical two-stage restricted SMART as in Figure 1 where response status is defined using the cut-point $c = 0$ (i.e., cocaine abstainers are responders). The longitudinal outcome will be measured at the end of each month, over a sixmonth period (i.e., $T = 6$), and randomization of non-responders occur immediately after the second measurement occasion (i.e., $K = 2$) where the pair of EDTRs (+1,+1) and (-1,+1) are compared using either difference in end-of-study means $(i.e., \Delta_{\rm EOS} = E\left\{Y_{i,t_6}^{(+1, +1)}\right\} E\left\{Y_{i,t_6}^{(-1,+1)}\right\}$ or difference in AUC (*i.e.*, $\Delta_{\text{AUC}} = \text{AUC}^{(+1,+1)} - \text{AUC}^{(-1,+1)}$), each at a desired type-I error rate of $\alpha = 0.05$. $M = 5000$ Monte Carlo samples were used to calculate power. *5.1 Simulation Study 1*

Although the Z-test derived from Theorem 2.1 is expected to perform well asymptotically, it is valuable to use simulations to investigate its performance with finite sample sizes. Simulation Study 1 is designed to evaluate the test's performance by examining the empirical type-I error rate when $\Delta_{EOS} = 0$ and $\Delta_{AUC} = 0$. Across all scenarios, total sample size N, proportion of responders p and q, ETS means, and τ_{MAX} were held constant. Three scenarios corresponding to increased ETS proportion of zeros were considered. Table 1 displays the varying values of parameters used in Simulation Study 1.

5.2 Simulation Study 2

Simulation Study 2 is designed to investigate how power changes as Δ_{EOS} and Δ_{AUC} increase. Across all scenarios, proportions of responders p and q , ETS proportion of zeros, and τ_{MAX} were held constant as power was calculated across the grid 100, 150, 200, ... 550, 600 for total sample size N. Ten scenarios corresponding to increased magnitude of Δ_{EOS} and Δ_{AUC} were considered. Table 1 displays the varying values of parameters used in Simulation Study 2;

altogether, these values imply the following values for Δ_{EOS} and Δ_{AUC} in scenarios 1-10: Δ_{EOS} = 0 (scenario 1), 0.195 (scenario 2), 0.390 (scenario 3), 0.585 (scenario 4), 0.780 (scenario 5), 0.975 (scenario 6), 1.170 (scenario 7), 1.365 (scenario 8), 1.560 (scenario 9), 1.755 (scenario 10); and $\Delta_{AUC} = 0$ (scenario 1), 0.892 (scenario 2), 1.785 (scenario 3), 2.677 (scenario 4), 3.570 (scenario 5), 4.463 (scenario 6), 5.355 (scenario 7), 6.248 (scenario 8), 7.140 (scenario 9), 8.033 (scenario 10). Additionally, to investigate how power changes as τ_{MAX} increases, we repeated the scenarios described above, but increased the values of τ_{MAX} . We note that throughout scenarios 1-10, the magnitude of Δ_{EOS} and Δ_{AUC} remained identical even at increased values of τ_{MAX} .

5.3 Simulation Study 3

Simulation Study 3 is designed to investigate whether power is sensitive to violation of the working assumption made with respect to subgroup 4, namely that the number of individuals in subgroup 4 (n_4) is equal to the minimum number of non-responders to either of the 2 initial interventions. Ten scenarios identical to those described in Simulation Study 2 were considered, except that the total sample size N was fixed to 500 and τ_{MAX} was fixed to 0.7. Within each scenario, the working assumption was violated by calculating power when n_4 was set to 0, 10, 20, 30, 40 …, 180, 190 (i.e., the maximum possible value of n_4).

5.4 Simulation Study 4

Rather than unrealistically requiring clinical/behavioral experts to specify a large number of different correlations in advance, our proposed approach only requires eliciting the maximum within-person correlation (i.e., τ_{MAX}) as an input to power calculation. However, this approach might lead to a degree of misspecification. In order to provide practical guidance to trial planners on the selection of a value for the copula dependence parameter ρ , Simulation Study 4 is designed to investigate the minimum (τ_{MIN}) and maximum (τ_{MAX}) within-person correlation

 $\mathit{Corr}\left(Y_{i,t_{j'}}^{s'}\right)$ $s'_{,t_{j'}}$, $Y_{i,t_{j''}}^{s''}$ $\binom{s''}{t}$ possible given specific values of ρ . We consider the three scenarios identical to that described in Simulation Study 1. In each of the three scenarios, we fix the value of ρ to the values 0.05, 0, 0.05, 0.10, 0.15..., 0.95, 1, and then calculate τ_{MIN} and τ_{MAX} for each value of ρ (see Web Appendix D for more detail).

6. Simulation Study Results

The results for Simulation Study 1 are summarized in Figure 2 where total sample size N (x-axis) is plotted against the empirical type-I error rate (y-axis). The results show slightly above nominal empirical type-I error rate (i.e., 0.05 to 0.07) when the proportion of zeros are relatively low (ranging from 0.52 to 0.65; top panels) and slightly below nominal empirical type-I error rate (i.e., 0.04 to 0.05) when the proportion is zeros is relatively high (ranging from 0.60 to 0.87; bottom panels).

The results for Simulation Study 2 are summarized in Figure 3 where total sample size N (x-axis) is plotted against power (y-axis). Scenarios 1-10 are represented by the solid dots on the first through tenth layer, respectively. The power curves indicate that power increases as Δ_{EOS} and Δ_{AUC} increase, with similar trends observed when τ_{MAX} is fixed to 0.4, 0.7 and 0.1. Further, the results show that given a particular value for Δ_{EOS} , high within-person correlation can increase power for detecting differences in end-of-study means. For example, consider scenario 10 where $\Delta_{EOS} = 1.755$: when $\tau_{MAX} = 0.7$, a sample size of $N = 450$ is required to achieve power of 0.80 (see top panel), but when $\tau_{MAX} = 0.1$, a sample size of $N=500$ is required to achieve power of 0.80 (see bottom panel). In contrast, given a particular value for Δ_{AUC} , high withinperson correlation can decrease power for detecting differences in AUC. For example, consider scenario 10 where Δ_{AUC} =8.033: when τ_{MAX} = 0.7 (see top panel), a sample size of N=400 is

required to achieve power of 0.80, but when $\tau_{MAX} = 0.1$ (see bottom panel), a sample size of $N=250$ is required to achieve power of 0.80.

The results for Simulation Study 3 are summarized in Figure 4 where n_4 (x-axis) is plotted against power (y-axis). Scenarios 1-10 are represented by the solid dots on the first through tenth layer, respectively. The results show that across the ten scenarios, power is not sensitive to the actual value of n_4 .

Finally, the results for Simulation Study 4 are summarized in Figure 5 where for each fixed value of ρ (x-axis), the corresponding value of τ_{MIN} and τ_{MAX} (y-axis) are displayed. The results show that across all values of ρ , the difference between τ_{MIN} and τ_{MAX} does not exceed 0.10, 0.17, and 0.33 for scenarios with low, moderate, and high zeros, respectively.

7. Discussion

The current manuscript addresses an important gap in sample size planning for SMARTs by introducing a Monte Carlo-based approach for estimating the sample size needed to compare two DTRs embedded in a SMART using longitudinal count outcome data with EZ. This approach is designed to require only specification of parameters that clinical/behavioral experts can meaningfully interpret and can hence draw on existing empirical evidence and practical consideration to specify. Simulation studies indicate that this method generally performs well in terms of empirical type-I error rate, showing anticipated increases in power as the difference between embedded DTRs increase, and little sensitivity to violation of working assumptions. The results also show that while high within-person correlation increases power for detecting differences in end-of-study means, it decreases power for detecting differences in AUC. These results are expected given that the AUC is analogous to a within-cluster average, such that high within-person correlation represents less independent information per cluster (here, a person).

Meanwhile, comparing end-of-study means with randomized data, under the assumption of group equivalence prior to randomization, is more similar to analysis of covariance, such that high within-person correlation allows baseline variance to be accounted for and reduce standard error for the difference.

The simulation studies also point to several limitations in our approach and directions for future research. In Simulation Study 1, scenarios with relatively low rates of zeros show slightly above nominal type-I error rate. This is consistent with evidence outside the SMART setting showing inflated empirical type-I error rates in Wald tests concerning count data with EZ (e.g., (Yu, et al., 2013)). On the other hand, scenarios with relatively high rates of zeros show a slightly below nominal empirical type-I error rate. Further investigation into the results of Simulation Study 1 (see Web Appendix E) showed that estimates of $\sqrt{Var(\hat{A}_{EOS}^{IPWRE})}$ were

unbiased but estimates of $\sqrt{Var(\hat{\Delta}_{AUC}^{IPWRE})}$ exhibited a pronounced downward bias when the total sample size N is below 200. This bias was attenuated as N was increased, particularly in the scenario with high rates of zero. Outside the SMART setting, other authors have observed that score tests using the Normal approximation may underestimate nominal type-I error rate (Jung, Jhun, and Lee, 2005). These results suggest that Taylor series arguments used by Lu and colleagues (Lu, et al., 2016) to derive an expression for $\widehat{Var}(\widehat{\beta}^{IPWRE})$ may not approximate well the true value $Var(\hat{\beta}^{IPWRE})$ in scenarios with relatively high rates of zeros. Nonetheless, the results of Simulation Study 1 indicate that type-I error rate was close to nominal (i.e., within the 0.04 to 0.06 range) in most conditions. If the available N is small or the proportion of zeroes is expected to be large, the use of bootstrap based approaches to approximating the variance of the estimated difference between embedded DTRs should be explored.

Finally, the results in Simulation Study 4 indicate that the shortcut of using the maximum expected correlation τ_{MAX} to select the value of the simulated data dependence parameter ρ is adequate in many situations. However, this approach may not be appropriate in extreme conditions, such as scenarios with high rates of zeros, where the difference $\tau_{MAX} - \tau_{MIN}$ can be substantial. When such conditions are anticipated, trial planners may consider selecting the value of ρ which will yield either much smaller or much larger value of τ_{MAX} than the actual value elicited from clinical/behavioral experts to correct for possible over-estimation or underestimation of power, as a kind of sensitivity analysis.

Despite the limitations, the current manuscript provides a novel simulation strategy which addresses an important practical need in planning SMARTs with longitudinal outcomes using elicitable and interpretable parameters. The simulation strategy outlined here, combining use of principal stratification and copulas, can readily be extended to other types of outcome variables, such as binary outcomes, in addition to the count variables with EZ considered here.

References

- Albert, J. M., and Nelson, S. (2011). Generalized causal mediation analysis. *Biometrics, 67*(3), 1028-1038.
- Albert, J. M., Wang, W., and Nelson, S. (2014). Estimating overall exposure effects for zeroinflated regression models with application to dental caries. *Statistical Methods in Medical Research, 23*(3), 257-278.
- Collins, L. M., Murphy, S. A., and Bierman, K. L. (2004). A conceptual framework for adaptive preventive interventions. *Prevention Science, 5*(3), 185-196.
- Frangakis, C. E., Rubin, D. B., An, M. W., and MacKenzie, E. (2007). Principal stratification designs to estimate input data missing due to death. *Biometrics, 63*(3), 641-649.
- Jung, B. C., Jhun, M., and Lee, J. W. (2005). Bootstrap tests for overdispersion in a zero‐inflated poisson regression model. *Biometrics, 61*(2), 626-628.
- Kidwell, K. M., Seewald, N. J., Tran, Q., Kasari, C., and Almirall, D. (2018). Design and analysis considerations for comparing dynamic treatment regimens with binary outcomes from sequential multiple assignment randomized trials. *Journal of Applied Statistics, 45*(9), 1628-1651.
- Lavori, P. W., and Dawson, R. (2000). A design for testing clinical strategies: biased adaptive within-subject randomization. *Journal of the Royal Statistical Society: Series A, 163*(1), 29-38.
- Lei, H., Nahum-Shani, I., Lynch, K., Oslin, D., and Murphy, S. A. (2012). A "smart" design for building individualized treatment sequences. *Annual Review of Clinical Psychology, 8*, 21-48.
- Li, Z., and Murphy, S. A. (2011). Sample size formulae for two-stage randomized trials with survival outcomes. *Biometrika, 98*(3), 503-518.
- Lu, X., Nahum-Shani, I., Kasari, C., Lynch, K., Oslin, D., Pelham, W., Fabiano, G., and Almirall, D. (2016). Comparing treatment regimes using repeated-measures outcomes: modeling considerations in smart studies. *Statistics in Medicine, 35*(10), 1595-1615.
- Madsen, L., and Birkes, D. (2013). Simulating dependent discrete data. *Journal of Statistical Computation and Simulation, 83*(4), 677-691.
- McKay, J. R., Drapkin, M. L., Van Horn, D. H. A., Lynch, K. G., Oslin, D. W., DePhillipps, D., Ivey, M., and Cacciola, J. S. (2015). Effect of patient choice in an adaptive sequential randomization trial of treatment for alcohol. *Journal of Consulting and Clinical Psychology, 83*(6), 1021.
- Miyahara, S., and Wahed, A. S. (2012). Assessing the effect of treatment regimes on longitudinal outcome data: application to REVAMP study of depression. *Journal of Statistical Research, 46*(2), 233-254.
- Murphy, S. A. (2005). An experimental design for the development of adaptive treatment strategies. *Statistics in Medicine, 24*(10), 1455-1481.
- Rubin, D. B. (2005). Causal inference using potential outcomes: Design, modeling, decisions. *Journal of the American Statistical Association, 100*(469), 322-331.
- Seewald, N. J., Kidwell, K. M., Nahum-Shani, I., Wu, T., McKay, J. R., and Almirall, D. (2020). Sample size considerations for comparing dynamic treatment regimens in a sequential multiple-assignment randomized trial with a continuous longitudinal outcome. *Statistical Methods in Medical Research, 29*(7), 1891-1912.
- Song, P. (2000). Multivariate dispersion models generated from Gaussian Copula. *Scandanavian Journal of Statistics, 27*(2), 305-320.
- Yu, Q., Chen, R., Tang, W., He, H., Gallop, R., Crits-Christoph, P., Hu, J., and Tu, X. M. (2013). Distribution-free models for longitudinal count responses with overdispersion and structural zeros. *Statistics in Medicine, 32*(14), 2390-2405.

Supporting Information

Web Appendices, Tables, and Figures referenced in Sections 2, 4, 5, 6, 7 are available with this manuscript at the Biometrics website on Wiley Online Library. Code utilized for this manuscript is available at<https://github.com/jamieyap/CountSMART>

Figures

*Total sample size (x-axis) vs. Empirical Type-I Error Rate (y-axis) Difference in end-of-study means Difference in AUC***Low Zeros Low Zeros** 0.08 Empirical Type-I Error Rate
0.02 0.04 0.06 0.08 Empirical Type-I Error Rate
0.02 0.04 0.06 0. Ċ 100 100 600 200 300 500 600 200 500 400 300 400 N N **Moderate Zeros Moderate Zeros** 0.08 Empirical Type-I Error Rate
0.02 0.04 0.06 0.08 Empirical Type-I Error Rate
0.02 0.04 0.06 0. 100 100 200 500 600 600 300 200 300 500 400 400 N N **High Zeros High Zeros** 0.08 Empirical Type-I Error Rate
0.02 0.04 0.06 0.08 Empirical Type-I Error Rate 0.06 0.04 0.02 200 600 100 300 500 100 200 300 600 400 400 500 N N

Figure 2: Results of Simulation Study 1. This figure appears in color in the electronic version of this article.

this article.

Page **30** of **34**

Figure 4: Results of Simulation Study 3. This figure appears in color in the electronic version of

this article.

Figure 5: Results of Simulation Study 4. This figure appears in color in the electronic version of

this article.

Tables

Supporting Information for 'Planning SMARTs: Sample size estimation for comparing dynamic treatment regimens using longitudinal count outcomes with excess zeros' by JAMIE YAPª, JOHN DZIAK^b, RAJU MAITI^c, KEVIN LYNCH^f, JIM MCKAY^f, BIBHAS CHAKRABORTY^{c,d,e}, INBAL NAHUM-SHANI^a a Institute for Social Research, Ann Arbor, MI, USA ^bBennett Pierce Prevention Research Center, Pennsylvania State University, PA, USA ^cCentre for Quantitative Medicine, Duke-NUS Medical School, Singapore ^dDepartment of Statistics and Applied Probability, National University of Singapore, Singapore ^eDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA

^fDepartment of Psychiatry, University of Pennsylvania, PA, USA

jamieyap@umich.edu

Web Appendix A. Estimation of Δ_0 using a longitudinal EZ count outcome

Although IPWRE is applicable to many kinds of outcomes, the illustration and simulation studies of Lu and colleagues (Lu et al., 2016) focused on a continuous longitudinal outcome. Here, we provide details on estimation of $\Delta_{\mathcal{Q}}$ using IPWRE when the longitudinal outcome is count with EZ and a log-link function. We begin by noting that for any given pair of EDTRs $(a_1', a_2^{NR'})$ and $(a_1'', a_2^{NR''})$ and set of real-valued constants l_j 's, the quantity Δ_Q can be reexpressed as in Equation 1.

$$
\Delta_Q = \mathit{Lexp}\left[\mathbf{C}^{\left(a_1', a_2^{NR'}\right)}\boldsymbol{\beta}\right] - \mathit{Lexp}\left[\mathbf{C}^{\left(a_1'', a_2^{NR''}\right)}\boldsymbol{\beta}\right]
$$
\n⁽¹⁾

In Equation 1, $C^{(a_1, a_2^{NR})}$ denotes a $T \times (4T - 2K - 1)$ matrix of 1's and 0's, specifying which of the $4T - 2K - 1$ parameters is associated with EDTR (a_1, a_2^{NR}) ; $exp[\cdot]$ denotes element-wise exponentiation; \boldsymbol{L} is $1 \times T$ matrix whose elements are the real-valued constants

 l_j 's. The specific form of $C^{(a_1,a_2^{NR})}$ is chosen so that the term $exp\left[C^{(a_1,a_2^{NR})}\beta\right]$, which we denote more succinctly by $\mathbf{U}_{\beta}^{(a_1, a_2^{NR})}$, results in a diagonal matrix having the mean trajectory of EDTR (a_1, a_2^{NR}) , i.e., $\tau^{(a_1, a_2^{NR})}$, as elements on its diagonal.

For example, when second-stage randomization occurs at the second measurement occasion and there are six measurement occasions in total i.e., $K = 2, T = 6$, then the mean trajectory of the longitudinal outcome can be modeled by Equation 2. In terms of the parameters $\beta_{m,j}$'s in Equation 2, the mean trajectory the EDTRs, i.e., $\tau^{(+1,+1)}$, $\tau^{(+1,-1)}$, $\tau^{(-1,+1)}$, and $\tau^{(-1,-1)}$, are then given by Web Table 1.

$$
\log \left(\mu_{t_j}^{(a_1, a_2^{NR})} \right) = \beta_{1,1} + I(a_1 = +1) \cdot \beta_{2,2}
$$

+ $I(a_1 = -1) \cdot \beta_{3,2}$
+ $I(a_1 = +1, a_2^{NR} = +1) \cdot I(2 < j \le 6) \cdot \beta_{4,j}$
+ $I(a_1 = +1, a_2^{NR} = -1) \cdot I(2 < j \le 6) \cdot \beta_{5,j}$
+ $I(a_1 = -1, a_2^{NR} = +1) \cdot I(2 < j \le 6) \cdot \beta_{6,j}$
+ $I(a_1 = -1, a_2^{NR} = -1) \cdot I(2 < j \le 6) \cdot \beta_{7,j}$ (2)

After a model for the mean trajectory of EDTRs has been specified, e.g., as in Equation 2, the steps required to obtain $\hat{\beta}^{IPWRE}$ using a longitudinal EZ count outcome is identical to the approach one would employ when using either a longitudinal continuous or binary outcome. We direct readers to literature providing details of the steps involved (see (Dziak, et al., 2019; Nahum-Shani, et al., 2020; Seewald, et al., 2020; Lu et al., 2016)); the R package *geeM* (McDaniel, Henderson, and Rathouz, 2013) was utilized in this manuscript's implementation of IPWRE. Once an estimate for β has been obtained (i.e., $\hat{\beta}^{IPWRE}$), an estimate for Δ_0 can be simply calculated by substituting β with its estimate in Equation 2. In other words, once $\widehat{\beta}^{IPWRE}$

has been obtained, $\hat{\Delta}_{Q}^{IPWRE}$ can simply be calculated by applying an appropriate matrix product to $\hat{\beta}^{IPWRE}$ (a matrix product based on Equation 1).

Finally, we note that in the specific example of using Equation 2 as a model for the mean trajectory of EDTRs, we specify the matrices in Equation 1 as follows: β : =

$$
(\beta_{1,1} \quad \beta_{2,2} \quad \beta_{3,2} \quad \boldsymbol{\beta}^{(+1,+1)^{T}} \quad \boldsymbol{\beta}^{(+1,-1)^{T}} \quad \boldsymbol{\beta}^{(-1,+1)^{T}} \quad \boldsymbol{\beta}^{(-1,-1)^{T}} \right)^{T} \text{ where } \boldsymbol{\beta}^{(+1,+1)} =
$$
\n
$$
(\beta_{4,3} \quad \beta_{4,4} \quad \beta_{4,5} \quad \beta_{4,6})^{T}, \boldsymbol{\beta}^{(+1,-1)} = (\beta_{5,3} \quad \beta_{5,4} \quad \beta_{5,5} \quad \beta_{5,6})^{T}, \boldsymbol{\beta}^{(-1,+1)} =
$$
\n
$$
(\beta_{6,3} \quad \beta_{6,4} \quad \beta_{6,5} \quad \beta_{6,6})^{T}, \boldsymbol{\beta}^{(-1,-1)} = (\beta_{7,3} \quad \beta_{7,4} \quad \beta_{7,5} \quad \beta_{7,6})^{T} \text{ and the matrices } \mathbf{C}^{(+1,+1)},
$$
\n
$$
\mathbf{C}^{(+1,-1)}, \mathbf{C}^{(-1,+1)}, \mathbf{C}^{(-1,-1)} \text{ are defined as:}
$$

$$
C^{(+1,+1)}: = (M^{(+1)} \quad M \quad 0_{6\times12})
$$
\n
$$
C^{(+1,-1)}: = (M^{(+1)} \quad 0_{6\times4} \quad M \quad 0_{6\times8})
$$
\n
$$
C^{(-1,+1)}: = (M^{(-1)} \quad 0_{6\times8} \quad M \quad 0_{6\times4})
$$
\n
$$
C^{(-1,-1)}: = (M^{(-1)} \quad 0_{6\times12} \quad M)
$$

where $\mathbf{0}_{m_1 \times m_2}$ denotes an $m_1 \times m_2$ matrix whose elements are all zero, and the matrices $\mathbf{M}^{(+1)}$, $M^{(-1)}$, and M are:

$$
M^{(+1)} := \begin{pmatrix} 1 & 0 & 0 \\ 1 & 1 & 0 \\ 1 & 0 & 0 \\ 1 & 0 & 0 \\ 1 & 0 & 0 \end{pmatrix}, M^{(-1)} := \begin{pmatrix} 1 & 0 & 0 \\ 1 & 0 & 0 \\ 1 & 0 & 1 \\ 1 & 0 & 0 \\ 1 & 0 & 0 \end{pmatrix}, M := \begin{pmatrix} 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \\ 1 & 0 & 0 & 0 \\ 0 & 1 & 0 & 0 \\ 0 & 0 & 1 & 0 \\ 0 & 0 & 0 & 1 \end{pmatrix}
$$

Web Appendix B. Proof of Theorem 2.1

We begin by observing that $Var(\widehat{\Delta}_Q^{IPWRE})$ can be expressed in terms of the covariance of a matrix product involving the quantity $Cov(\widehat{\pmb \beta}^{IPWRE}),$ i.e., as $Var(\widehat{\Delta}_Q^{IPWRE})=$ $Cov((DU_{\hat{\beta}}^I)^I^{IVRE}) \cdot \hat{\beta}^{I^{IVRE}}$ where **D**, $U_{\hat{\beta}^I}^{IVRE}$, and **C** are the block matrices defined below:

$$
D = (L - L) \tU_{\hat{\beta}^{IPWRE}} = \begin{pmatrix} U_{\hat{\beta}^{IPWRE}}^{(a_1', a_2^{NR'})} & 0_{T \times T} \\ 0_{T \times T} & U_{\hat{\beta}^{IPWRE}}^{(a_1'', a_2^{NR'})} \end{pmatrix} \tC = \begin{pmatrix} C^{(a_1', a_2^{NR'})} \\ C^{(a_1'', a_2^{NR'})} \end{pmatrix}
$$

Here, $U_{\beta}^{(+1,+1)}$ is then given by Equation 3 when $T=6$ and Equation 2 is utilized as a model for the EDTR mean trajectories; the matrices $U_{\beta}^{(+1,+1)}$, $U_{\beta}^{(+1,-1)}$, $U_{\beta}^{(-1,+1)}$, $U_{\beta}^{(-1,-1)}$ are defined analogously for other values of K or T .

$$
\boldsymbol{U}_{\beta}^{(+1,+1)} = \begin{pmatrix} e^{\beta_{1,1}} & 0 & 0 & 0 & 0 & 0 \\ 0 & e^{\beta_{1,1} + \beta_{2,2}} & 0 & 0 & 0 & 0 \\ 0 & 0 & e^{\beta_{1,1} + \beta_{4,3}} & 0 & 0 & 0 \\ 0 & 0 & 0 & e^{\beta_{1,1} + \beta_{4,4}} & 0 & 0 \\ 0 & 0 & 0 & 0 & e^{\beta_{1,1} + \beta_{4,5}} & 0 \\ 0 & 0 & 0 & 0 & 0 & e^{\beta_{1,1} + \beta_{4,5}} \end{pmatrix}
$$
(3)

By application of the delta method (Taylor linearization), we have that $\sqrt{N}(\widehat{\Delta}_{Q}^{IPWRE} \Delta_Q$) is asymptotically MVN with zero mean and covariance $Var(\sqrt{N} \, \widehat{\Delta}_Q^{IPWRE})$, where $Var(\hat{\Delta}_Q^{IPWRE})$ can be expressed as in Equation 4. Hence, we have that $Z = \frac{\hat{\Delta}_Q^{IPWRE} - \Delta_Q}{\sqrt{Q}}$ $\sqrt{Var(\hat{\Delta}_Q^{IPWRE})}$ is

 $Normal(0,1)$ distributed.

$$
Var(\widehat{\Delta}_{Q}^{IPWRE}) = (DU_{\widehat{\beta}^{IPWRE}}C) \cdot Cov(\widehat{\beta}^{IPWRE}) \cdot (DU_{\widehat{\beta}^{IPWRE}}C)^{T}
$$
 (4)

Now, let $\hat{\Sigma}_{\hat{\beta}}$ IPWRE denote an estimator for $Cov(\sqrt{N}\,\hat{\beta}^{IPWRE})$ proposed by Lu and colleagues (see Theorem I.2 in Supplementary Material (Lu et al., 2016). Then by Slutsky's Theorem, $Var(\hat{A}_Q^{IPWRE})$ is approximated by Equation 5.

$$
\widehat{Var}(\hat{\Delta}_Q^{IPWRE}) = (\boldsymbol{DU}_{\hat{\beta}^{IPWRE}}) \cdot \frac{\widehat{\Sigma}_{\hat{\beta}^{IPWRE}}}{N} \cdot (\boldsymbol{DU}_{\hat{\beta}^{IPWRE}}C)^{T}
$$
\n⁽⁵⁾

Again, by Slutsky's Theorem, we have that $Z = \frac{\hat{\Delta}_Q^{IPWRE} - \Delta_Q}{\sqrt{2\pi} \hat{\Delta}_Q^{I}}$ $\sqrt{Var\left(\widehat{\Delta}_{Q}^{IPWRE}\right)}$ is *Normal*(0,1) distributed. ■

Web Appendix C. Approach to generate draws from the multivariate distribution of θ_i^{SGj}

Our application of the method proposed by Madsen and Birkes (Madsen and Birkes, 2013) consists of three steps. Here, d_j denotes the dimension of θ_i^j and $\mathbf{0}_{m_1 \times m_2}$ denotes an $m_1 \times m_2$ matrix whose elements are all zero.

- 1. Generate n_j independent draws from a multivariate standard normal distribution with mean $\mathbf{0}_{d_j \times 1}$ and correlation matrix Γ_{d_j} , i.e., $\mathbf{Z}^{(\ell)} \sim MVN\left(\mathbf{0}_{d_j \times 1}, \Lambda_{d_j}\right)$, $\ell = 1, 2, ..., n_j$. In the manuscript, Λ_{d_j} is exchangeable, i.e., $\Lambda_{d_j} = I_{d_j \times d_j} + \rho \left(\mathbf{1}_{d_j \times 1} \mathbf{1}_{d_j \times 1}^T - I_{d_j \times d_j} \right)$ where $\mathbf{1}_{m_1 \times m_2}$ denotes an $m_1 \times m_2$ matrix whose elements are all zero and one and $I_{m_1 \times m_2}$ denotes an $m_1 \times m_2$ identity matrix.
- 2. Denote the vectors $\mathbf{Z}^{(\ell)}$ and $\mathbf{U}^{(\ell)}$ by $\mathbf{Z}^{(\ell)} := \begin{pmatrix} Z_1^{(\ell)} & \dots & Z_{d_j}^{(\ell)} \end{pmatrix}^T$ and $\mathbf{U}^{(\ell)} :=$

$$
\left(U_1^{(\ell)} \cdots U_{d_j}^{(\ell)}\right)^T
$$
. For each $\ell = 1, 2, \ldots, n_j$, generate a new vector $U^{(\ell)}$ by applying a transformation using the univariate standard normal CDF to each component of $\mathbf{Z}^{(\ell)}$.
That is, $\left(U_1^{(\ell)} \cdots U_{d_j}^{(\ell)}\right) = \left(\phi\left(Z_1^{(\ell)}\right) \cdots \phi\left(Z_{d_j}^{(\ell)}\right)\right)$.

3. For each $\ell = 1, 2, ..., n_j$, generate a new vector $X^{(\ell)}$ by applying a transformation using the inverse of the CDF of a univariate count distribution to each component of $U^{(\ell)}$. That is, if $X^{(\ell)} = \begin{pmatrix} X_1^{(\ell)} & \dots & X_{d_j}^{(\ell)} \end{pmatrix}$ and F_1, \dots, F_{d_j} denotes an appropriate CDF of a univariate count distribution corresponding to components $1, \ldots, d_j$ respectively, of $U^{(\ell)}$, then

$$
\begin{pmatrix} X_1^{(\ell)} & \dots & X_{d_j}^{(\ell)} \end{pmatrix} = \left(F_1^{-1} \left(U_1^{(\ell)} \right) & \dots & F_{d_j}^{-1} \left(U_{d_j}^{(\ell)} \right) \right).
$$

Hence, each $X^{(\ell)}$ is effectively a draw of θ_i^j from its multivariate distribution where the CDFs 1, … , are given by Web Table 4 and Web Table 5. The R package *mvtnorm* (Genz and Bretz, 2009; Genz, et al., 2020) was utilized to draw from a multivariate normal (MVN) distribution.

Web Appendix D. Approach to estimate the relationship between ρ , τ_{MIN} , and τ_{MAX}

For each value of ρ in a grid, e.g., 0, 0.05, ..., 0.95, 1, we estimate τ_{MAX} and τ_{MIN} by using $\mathbb{P}_M\{\hat{\tau}_{MAX}\}\$ and $\mathbb{P}_M\{\hat{\tau}_{MIN}\}\$, respectively, calculated using the procedure below.

- 1. A large number of simulated SMART datasets, M , consisting of a large number of individuals each, N^* , would be generated based values of design parameters specified previously; data-generation would follow that described in Section 4.3, with only the final step on simulating sequential randomizations omitted.
- 2. For each simulated dataset, six vectors as follows:
	- Y_i^A : = $(Y_{i,t_1}^{(\cdot)} \cdots Y_{i,t_K}^{(\cdot+1)} Y_{i,t_{K+1}}^{(\cdot+1,1,0)} \cdots Y_{i,t_T}^{(\cdot+1,1,0)})^T$ using individuals belonging

to subgroups 1 and 2

• Y_i^B : = $\begin{pmatrix} Y_{i,t_1}^{(\cdot)} & \cdots & Y_{i,t_K}^{(\cdot+1),0,+1} \end{pmatrix}^T$ \cdots $Y_{i,t_T}^{(\cdot+1,0,+1)}$ $\begin{pmatrix} Y_{i,t_T}^{(\cdot+1,0,+1)} \end{pmatrix}^T$ using individuals

belonging to subgroups 3 and 4

• $Y_i^C := (Y_{i,t_1}^{(\cdot)} \cdots Y_{i,t_K}^{(\cdot+1)} Y_{i,t_{K+1}}^{(\cdot+1,0,-1)} \cdots Y_{i,t_T}^{(\cdot+1,0,-1)})^T$ using individuals

belonging to subgroups 3 and 4

• Y_i^D : = $(Y_{i,t_1}^{(\cdot)} \cdots Y_{i,t_K}^{(-1)}) Y_{i,t_{K+1}}^{(-1,1,0)} \cdots Y_{i,t_T}^{(-1,1,0)})^T$ using individuals belonging

to subgroups 1 and 3

• Y_i^E : = $(Y_{i,t_1}^{(\cdot)} \cdots Y_{i,t_K}^{(-1)}) Y_{i,t_{K+1}}^{(-1,0,+1)}) \cdots Y_{i,t_T}^{(-1,0,+1)})^T$ using individuals

belonging to subgroups 2 and 4

•
$$
Y_i^F
$$
: = $(Y_{i,t_1}^{(.)} \cdots Y_{i,t_K}^{(-1)} Y_{i,t_{K+1}}^{(-1,0,-1)} \cdots Y_{i,t_T}^{(-1,0,-1)})^T$ using individuals

belonging to subgroups 2 and 4

Using these vectors, a correlation matrix corresponding to Y_i^A , Y_i^B , Y_i^C , Y_i^D , Y_i^E , Y_i^F will be estimated and the quantities $\hat{\tau}_{MAX}$ and $\hat{\tau}_{MAX}$ (defined below) could then be calculated.

$$
\hat{\tau}_{MAX} := \max_{s', s'', \ t_j', t_{j'}} \left\{ \widehat{Corr} \left(Y_{i, t_{j'}}^{s'}, Y_{i, t_{j'}}^{s''} \right) \right\} \tag{6}
$$

$$
\hat{\tau}_{MIN} := \min_{s', s'', \ t_j', t_{j'}} \left\{ \widehat{Corr} \left(Y_{i, t_{j'}}^{s'}, Y_{i, t_{j'}}^{s''} \right) \right\} \tag{7}
$$

We note that in when $s' = s''$, the calculation of the maximum in and the minimum above will exclude the terms where $t_{j'} = t_{j''}$; for example, $\widehat{Corr}\left(Y_{i,t_2}^{(+1)}, Y_{i,t_2}^{(+1)}\right)$ will be excluded.

3. Finally, $\mathbb{P}_M\{\hat{\tau}_{MAX}\}$ and $\mathbb{P}_M\{\hat{\tau}_{MIN}\}$ is calculated as the mean of $\hat{\tau}_{MAX}$ and $\hat{\tau}_{MIN}$, respectively, across all simulated datasets.

Let $\hat{\tau}_{MAX}^{\rho}$ and $\hat{\tau}_{MIN}^{\rho}$ denote the value of $\mathbb{P}_{M}\{\hat{\tau}_{MAX}\}$ and $\mathbb{P}_{M}\{\hat{\tau}_{MIN}\}$ corresponding to a particular value of ρ which we calculate using the above-described approach. The value of ρ for which $\hat{\tau}_{MAX}^{\rho}$ closest to the desired value of τ_{MAX} will be selected and used to calculate power.

Web Appendix E. Supplement to Simulation Study 1

In Web Appendix E, we investigate whether the slightly above nominal or below nominal empirical type-I error rates observed in Simulation Study 1 can be attributed to bias in estimates of Δ_{EOS} and Δ_{AUC} , or bias in estimates of $\sqrt{Var(\hat{\Delta}_{EOS}^{IPWRE})}$ and $\sqrt{Var(\hat{\Delta}_{AUC}^{IPWRE})}$; we utilize values of design parameters identical to Simulation Study 1.

First, bias in estimates of $\Delta_{\rm EOS}$ and $\Delta_{\rm AUC}$ were estimated by calculating the average of the difference between the estimated and true value of $\Delta_{\rm EOS}$ and $\Delta_{\rm AUC}$. That is, bias is calculated as 1 $\frac{1}{M} \cdot \sum_{j=1}^{M} \left(\hat{\Delta}_{EOS}^{(j)} - \Delta_{EOS} \right)$ and $\frac{1}{M} \cdot \sum_{j=1}^{M} \left(\hat{\Delta}_{AUC}^{(j)} - \Delta_{AUC} \right)$, where $\hat{\Delta}_{EOS}^{(j)}$ $_{EOS}^{(j)}$ and $\hat{\Delta}_{AUC}^{(j)}$ $_{AHC}^{(j)}$ denotes the value of \hat{A}_{EOS}^{IPWRE} and \hat{A}_{AUC}^{IPWRE} , respectively, at the j^{th} simulated dataset. Note that values of design parameters in Simulation Study 1 were specified such that $\Delta_{EOS} = 0$ and $\Delta_{AUC} = 0$. As the left panels of Web Figure 1 show, estimates $\hat{\Delta}_{EOS}^{IPWRE}$ are unbiased. On the other hand, as the right panels of Web Figure 1 show, estimates \hat{A}_{AUC}^{IPWRE} exhibit slight bias which attenuates as total sample size N is increased.

Second, bias in estimates of $\sqrt{Var(\hat{\Delta}_{EOS}^{IPWRE})}$ and $\sqrt{Var(\hat{\Delta}_{AUC}^{IPWRE})}$ were estimated by calculating the average of the difference between the estimated value of $\sqrt{Var(\hat{A}_{EOS}^{IPWRE})}$ and $\sqrt{Var(\hat{\Delta}_{AUC}^{IPWRE})}$ and the empirical standard error of $\hat{\Delta}_{EOS}^{IPWRE}$ and $\hat{\Delta}_{AUC}^{IPWRE}$, respectively. Here, empirical standard error is calculated as the square root of the variance of $\hat{\Delta}_{EOS}^{IPWRE}$ and $\hat{\Delta}_{AUC}^{IPWRE}$ across all simulated datasets. That is, bias is calculated as $\frac{1}{M} \cdot \sum_{j=1}^{M} (\hat{\sigma}_{EOS}^{(j)} - \sigma_{EOS})$ and $\frac{1}{M} \cdot$ $\sum_{j=1}^{M}(\hat{\sigma}_{AUC}^{(j)}-\sigma_{\text{AUC}})$, where $\hat{\sigma}_{EOS}^{(j)}$ and $\hat{\sigma}_{AUC}^{(j)}$ denotes the value of $\sqrt{\hat{Var}(\hat{\Delta}_{EOS}^{IPWRE})}$ and

 $\sqrt{\sqrt{a}r(\hat{\Delta}_{AUC}^{IPWRE})}$, respectively, at the j^{th} simulated dataset; σ_{EOS} and σ_{AUC} denotes the empirical standard error of $\hat{\Delta}_{EOS}^{IPWRE}$ and $\hat{\Delta}_{AUC}^{IPWRE}$, respectively. As the left panels of Web Figure 2 show, estimates of standard errors for differences in end-of-study means are unbiased. On the other hand, as the right panels of Web Figure 2 show, estimates of $\sqrt{Var(\hat{\Delta}_{AUC}^{IPWRE})}$ exhibit a

pronounced *downward* bias when total sample size N is below 200; the bias attenuated as N was increased. particularly in the 'High Zeros' scenario.

Taken together, these results suggest that Taylor series arguments used by Lu and colleagues (Lu et al., 2016) to derive an expression for $\widehat{Var}(\widehat{\beta}^{IPWRE})$ do not well approximate the true value $Var(\hat{\beta}^{IPWRE})$ for modest sample sizes in a 'High Zeros' scenario. Subsequently, these results suggest that $\widehat{Var}(\hat{\mathit{A}}_{Q}^{IPWRE})$ do not also well approximate the true value $Var(\hat{\Delta}_Q^{IPWRE})$ in a 'High Zeros' scenario. In the SMART setting, the bootstrap and its variants (e.g., adaptive m-out-of-n bootstrap) have been employed as a means to obtain valid inference when a Q-learning data-analytic approach is used to compare EDTRs in a SMART (Chakraborty, Murphy, and Strecher, 2010; Chakraborty, Laber, and Zhao, 2013), a situation when Taylor series arguments also lead to imprecise inference. Hence, developing a bootstrap-based approach to inference on marginal structural model-based data-analytic approaches such as the IPWRE is an area of future work which could subsequently be integrated with this manuscript's proposed overall strategy for sample size estimation.

Web Appendix F. Supplement to Simulation Study 4

We consider ten scenarios identical to that described in Simulation Study 2. In each of the ten scenarios, we fix the value of ρ to the values -0.05, 0, 0.05, 0.10, 0.15…, 0.95, 1, and then calculate τ_{MIN} and τ_{MAX} for each value of ρ (see Web Appendix D for more detail). We note that the simulation study here in Web Appendix F differs from that of the simulation study in Section 5.4 in that here in Web Appendix F, ETS proportion of zeros were held constant across all scenarios while ETS means were varied; in contrast, in Section 5.4, ETS proportion of zeros were varied while ETS means were held constant across all scenarios. Additionally, we note that in both simulation studies, the value of M and N^* was set to 1000 and 2000, respectively.

Simulation results when design parameters in Simulation Study 1 were utilized are summarized in the plot in Web Figure 3 where ρ (x-axis) is displayed against τ_{MIN} and τ_{MAX} (yaxis). Across all values of ρ , the difference between τ_{MIN} and τ_{MAX} not exceed 0.11 in all scenarios. These results suggest that, when selecting the value of ρ , trial planners should focus on the impact of ETS proportion of zeros on the difference between τ_{MIN} and τ_{MAX} , rather than the impact of the magnitude of ETS means on the difference between τ_{MIN} and τ_{MAX} .

Web Appendix G. Accommodation for Reproducibility of Results

In this section, we highlight notable features of the repository <https://github.com/jamieyap/CountSMART> that improve the likelihood of reproducibility of the results discussed in the current manuscript; from here onward, we will refer to this repository as the 'CountSMART repository'.

The CountSMART repository houses R code (R Core Team, 2020) used in the development of our proposed approach to sample size estimation. The R package *renv* (Ushey, 2020) was utilized to record the collection of software dependencies (e.g., R package version numbers) in a file named *renv.lock* within the CountSMART repository. The process for utilizing the file *renv.lock* to recreate the software environment used in the current manuscript is described within the *renv* documentation (Ushey, 2020).

References

Chakraborty, B., Laber, E., and Zhao, Y. (2013). Inference for optimal dynamic treatment regimes using an adaptive m-out-of-n bootstrap scheme. *Biometrics, 69*(3), 714-723.

- Chakraborty, B., Murphy, S., and Strecher, V. (2010). Inference for non-regular parameters in optimal dynamic treatment regimes. *Statistical Methods in Medical Research, 19*(3), 317- 343.
- Dziak, J. J., Yap, J. R., Almirall, D., McKay, J. R., Lynch, K. G., and Nahum-Shani, I. (2019). A data analysis method for using longitudinal binary outcome data from a SMART to compare adaptive interventions. *Multivariate Behavioral Research, 54*(5), 613-636.
- Genz, A., and Bretz, F. (2009). *Computation of Multivariate Normal and t Probabilities, series Lecture Notes in Statistics.* Heidelberg: Springer-Verlag.
- Genz, A., Bretz, F., Miwa, T., Mi, X., Leisch, F., Scheipl, F., and Hothorn, T. (2020). *mvtnorm: Multivariate Normal and t Distributions.* R package. Retrieved from https://CRAN.Rproject.org/package=mvtnorm
- Lu, X., Nahum-Shani, I., Kasari, C., Lynch, K. G.,; Oslin, D., Pelham, W., Fabiano, G., Almirall, D. (2016). Comparing treatment regimes using repeated-measures outcomes: modeling considerations in smart studies. *Statistics in Medicine, 35*(10), 1595-1615.
- Madsen, L., and Birkes, D. (2013). Simulating dependent discrete data. *Journal of Statistical Computation and Simulation, 83*(4), 677-691.
- McDaniel, L. S., Henderson, N. C., and Rathouz, P. J. (2013). Fast Pure R Implementation of GEE: Application of the Matrix Package. *The R journal, 5*(1), 181-187.
- Nahum-Shani, I., Almirall, D., Yap, J. R., McKay, J., Lynch, K. G., Freiheit, E. A., and Dziak, J. J. (2020). SMART longitudinal analysis: A tutorial for using repeated outcome measures

from SMART studies to compare adaptive interventions. *Psychological Methods, 25*(1), 1-29.

- R Core Team (2020). *R: A language and environment for statistical computing.* R R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/
- Seewald, N. J., Kidwell, K. M., Nahum-Shani, I., Wu, T., McKay, J. R., and Almirall, D. (2020). Sample size considerations for comparing dynamic treatment regimens in a sequential multiple-assignment randomized trial with a continuous longitudinal outcome. *Statistical Methods in Medical Research, 29*(7), 1891-1912.
- Ushey, K. (2020). *renv.* R package version 0.9.3. Retrieved from https://CRAN.Rproject.org/package=renv

Web Figures

Web Figure 1: Results of Supplement to Simulation Study 1 in Web Appendix E. This figure

Web Figure 2: Results of Supplement to Simulation Study 1 in Web Appendix E. This figure

appears in color in the electronic version of this article.

Web Figure 3: Results of Supplement to Simulation Study 4 in Web Appendix F. This figure

appears in color in the electronic version of this article.

Web Tables

Web Table 1: Rows display the mean trajectory of the longitudinal EZ count outcome under each of the four EDTRs in terms of the parameters $\beta_{m,j}$'s in Equation 2

		$\text{EDTR} \qquad E\left\{Y_{i,t_1}^{(a_1,a_2^{NR})}\right\} \ E\left\{Y_{i,t_2}^{(a_1,a_2^{NR})}\right\} \ E\left\{Y_{i,t_3}^{(a_1,a_2^{NR})}\right\} \ E\left\{Y_{i,t_4}^{(a_1,a_2^{NR})}\right\} \ E\left\{Y_{i,t_5}^{(a_1,a_2^{NR})}\right\} \ E\left\{Y_{i,t_6}^{(a_1,a_2^{NR})}\right\}$			
		(+1,+1) $\beta_{1,1} + \beta_{2,2}$ $\beta_{1,1} + \beta_{4,3}$ $\beta_{1,1} + \beta_{4,4}$ $\beta_{1,1} + \beta_{4,5}$ $\beta_{1,1} + \beta_{4,6}$			
$(+1,-1)$	$\beta_{1,1}$			$\beta_{1,1}+\beta_{2,2} \quad \ \beta_{1,1}+\beta_{5,3} \quad \ \beta_{1,1}+\beta_{5,4} \quad \ \beta_{1,1}+\beta_{5,5} \quad \ \beta_{1,1}+\beta_{5,6}$	
$(-1, +1)$	$\beta_{1,1}$			$\beta_{1,1}+\beta_{3,2} \quad \ \ \beta_{1,1}+\beta_{6,3} \quad \ \ \beta_{1,1}+\beta_{6,4} \quad \ \ \beta_{1,1}+\beta_{6,5} \quad \ \ \beta_{1,1}+\beta_{6,6}$	
$(-1,-1)$	$\beta_{1,1}$			$\beta_{1,1}+\beta_{3,2} \quad \ \beta_{1,1}+\beta_{7,3} \quad \ \beta_{1,1}+\beta_{7,4} \quad \ \beta_{1,1}+\beta_{7,5} \quad \ \beta_{1,1}+\beta_{7,6}$	

Web Table 2: The first row of the table below enumerates all possible potential outcomes corresponding to the SMART design in Figure 1 when there are three measurement occasions. Below, the potential outcomes Y_{i,t_j}^s is that would be feasible for an individual,

	V^{\backslash} i, t_1	$V^{(+1)}$ i, t_2	$V^{(-1)}$ I_{i,t_2}	$V^{(+1,1,0)}$ I_{i,t_3}	$V^{(+1,0, +1)}$ $i_{,t_3}$	$V^{(+1,0, +1)}$ $i_{,t_3}$	$V^{(-1,1,0)}$ i, t_3	$V^{(-1,0,+\overline{1})}$ i, t_3	$V^{(-1,0,-1)}$ $i_{,t_3}$
Subgroup 1	\checkmark	\checkmark	\checkmark	\checkmark			\checkmark	–	
Subgroup 2	\checkmark	\checkmark	\checkmark	\checkmark				\checkmark	\checkmark
Subgroup 3	\checkmark	\checkmark	\checkmark		\checkmark	\checkmark	\checkmark		
Subgroup 4	\checkmark	\checkmark	\checkmark		\checkmark	\checkmark		\checkmark	\checkmark

contingent on their subgroup membership, are denoted by a check-mark (\checkmark) .

Web Table 3: Constraints on the values of $Y_{i,t_2}^{(+1)}$ and $Y_{i,t_2}^{(-1)}$ for the four subgroups in a SMART are listed; these constrains are based on response status defined as $R_i^{(a_1)} = I\left(Y_{i,t_K}^{(a_1)} \le c\right)$ in this manuscript's exposition of the proposed approach to data generation.

	Constraint on the value of $Y_{i,t_2}^{(+1)}$	Constraint on the value of $Y_{i,t_2}^{(-1)}$
Subgroup 1	$Y_{i,t_2}^{(+1)} \leq c$	$Y_{i,t_2}^{(-1)} \leq c$
Subgroup 2	$Y_{i,t_2}^{(+1)} \leq c$	$Y_{i,t_2}^{(-1)} > c$
Subgroup 3	$Y_{i,t_2}^{(+1)} > c$	$Y_{i,t_2}^{(-1)} \leq c$
Subgroup 4	$Y_{i,t_2}^{(+1)} > c$	$Y_{i,t_2}^{(-1)} > c$

Web Table 4: The complete specification of the marginal distribution of the components of θ_i^{SG} for each subgroup is displayed. Below, c is a cut-point used in the definition of response status. The CDF of a negative binomial (NB), upper truncated negative binomial (UTNB), and lower truncated negative binomial (LTNB) distribution determined by c, $\mu_{t_j}^s$, and $\zeta_{t_j}^s$ is denoted by $F_{NB}(\mu_{t_j}^s, \zeta_{t_j}^s)$,

 $F_{\text{UpperTruncNB}\left(\mu_{\xi_j}^s,\zeta_{\xi_j}^s,c\right)},$ and $F_{\text{LowerTruncNB}\left(\mu_{\xi_j}^s,\zeta_{\xi_j}^s,c\right)},$ respectively. In terms of the probability mass function (PMF) of a NB random

variable f $\mathcal{S}_{NB}(\mu_{tj}^{s},\zeta_{tj}^{s})$, the PMF of a UTNB random variable and a LTNB random variable is f UpperTruncNB $\big(\mu^{\mathrm{s}}_{t_\mathrm{j}},\zeta^{\mathrm{s}}_{t_\mathrm{j}}.c\big)^{\mathrm{(}W\mathrm{)}}$ $=$

 $f_{NB\left(\mu_{t_j}^S,\zeta_{t_j}^S\right)}(w)I(w\leq c)$ $\Sigma_{y=0}^c f_{NB} \left(\mu_{t_j}^s, \zeta_{t_j}^s \right) (y)$ and f LowerTruncNB $\big(\mu^{\mathrm{s}}_{t_\mathrm{j}}$, $\zeta^{\mathrm{s}}_{t_\mathrm{j}}$, $c\big)^{\mathrm{(}W\mathrm{)}}$ = $f_{NB\left(\mu_{t_j}^S, \zeta_{t_j}^S\right)}(w)I(w>c)$ $1-\sum_{v=0}^{c}f$ $\frac{c}{s}$ (i) iii) $\frac{c}{s}$ (iii), respectively. When c=0, the UTNB PMF reduces to a point $\frac{c}{s}$ ($\frac{a}{s}$ ($\frac{a}{s}$ ($\frac{a}{s}$ ($\frac{a}{s}$ ($\frac{a}{s}$ ($\frac{a}{s}$))

mass at zero.

	$F_{Y_{i,t}}$	$F_{Y_{i,t_2}}^{(+1)}$	$F_{Y_{i,t_2}}^{(-1)}$
		Subgroup 1 $F_{NB(\mu_{t_1}^{(\cdot)}, \zeta_{t_1}^{(\cdot)})}$ $F_{UpperTruncNB(\mu_{t_2}^{(+1)}, \zeta_{t_2}^{(+1)}, c)}$ $F_{UpperTruncNB(\mu_{t_2}^{(-1)}, \zeta_{t_2}^{(-1)}, c)}$	
Subgroup 2		$F_{NB(\mu_{t_1}^{(1)}, \zeta_{t_1}^{(1)})}$ $F_{\text{UpperTruncNB}(\mu_{t_2}^{(+1)}, \zeta_{t_2}^{(+1)}, c)}$ $F_{\text{LowerTruncNB}(\mu_{t_2}^{(-1)}, \zeta_{t_2}^{(-1)}, c))}$	
Subgroup 3		$F_{NB(\mu_{t_1}^{(\cdot)}, \zeta_{t_1}^{(\cdot)})}$ $F_{LowerTruncNB(\mu_{t_2}^{(+1)}, \zeta_{t_2}^{(+1)}, c)}$ $F_{UpperTruncNB(\mu_{t_2}^{(-1)}, \zeta_{t_2}^{(-1)}, c)}$	
Subgroup 4		$F_{NB(\mu_{t_1}^{(\cdot)}, \zeta_{t_1}^{(\cdot)})}$ $F_{LowerTruncNB(\mu_{t_2}^{(+1)}, \zeta_{t_2}^{(+1)}, c)}$ $F_{LowerTruncNB(\mu_{t_2}^{(-1)}, \zeta_{t_2}^{(-1)}, c)}$	

Web Table 5: Web Table 4, Continued